financetom
Business
financetom
/
Business
/
Constellation Brands Issues Weak Full-Year Earnings Outlook Despite Fourth-Quarter Beat
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Constellation Brands Issues Weak Full-Year Earnings Outlook Despite Fourth-Quarter Beat
Apr 10, 2025 4:00 AM

06:44 AM EDT, 04/10/2025 (MT Newswires) -- Constellation Brands ( STZ ) shares declined early Thursday as it issued a full-year earnings outlook below market estimates, including tariff impact, while the beer and wine company reported better-than-expected fiscal fourth-quarter results.

Constellation anticipates comparable earnings to be in a range of $12.60 to $12.90 a share for fiscal 2026, it said late Wednesday, while the current consensus on FactSet is for $13.83. In the just-ended fiscal year, adjusted EPS climbed 11% to $13.78. The stock decreased 3.5% in the most recent premarket activity.

Enterprise organic sales are expected to range from a 2% decline to a 1% rise for the ongoing fiscal year, according to Constellation. Beer sales are forecast to be flat to up 3% while organic sales in the wine and spirits division are expected to fall by 17% to 20%.

The company said its guidance reflects the expected impact of US government tariffs announced last week and duties implemented by Canada on March 4. On Wednesday, President Donald Trump announced a 90-day pause on certain tariffs for non-retaliating countries. A lower tariff rate of 10% would be applicable during the period.

"Despite a softer consumer demand backdrop in fiscal 2025, we delivered another year of enterprise net sales growth and substantial comparable operating margin improvement, as well as double-digit comparable EPS growth," Chief Executive Bill Newlands said in a statement. "Looking ahead, in a tough socioeconomic environment we are taking decisive actions designed to continue to support our industry-leading Beer Business, reset our cost base, and redefine our portfolio."

In a separate statement, Constellation agreed to divest several of its mainstream wine brands such as Woodbridge and Meiomi, along with related vineyards and facilities, to The Wine Group for an undisclosed sum. The deal, subject to approval by regulators, is expected to close immediately after the end of Constellation's first quarter of fiscal 2026.

Constellation also said it's reviewing its organizational structure to refocus its wine and spirits portfolio on higher-margin brands priced largely at $15 and above. The review is projected to save the company more than $200 million in annualized costs by fiscal 2028.

"We do not see the merit in the wine divestiture (dilutive to earnings without improving the multiple) and have limited confidence in the beer volume outlook," Truist Securities said in a Wednesday client note. The brokerage has a hold rating on Constellation's stock.

For the three-month period ended February, the company posted adjusted EPS of $2.63 versus $2.30 the year before, surpassing the Street's view of $2.27. Net sales inclined 1% year over year to $2.16 billion, ahead of the average analyst estimate of $2.13 billion.

Beer revenue was nearly unchanged at $1.7 billion with shipment declines largely offset by pricing, according to Constellation. Sales of wine and spirits improved 5% to $459.8 million, amid volume gains in the group's US wholesale business and international markets. Both divisions' depletion rate, or the pace at which units are sold to end consumers, declined.

Constellation expects net sales to grow about 2% to 4% for the fiscal years 2027 and 2028, compared with its previous medium-term projections for a 6% to 8% gain. Beer sales are estimated to rise by the same range in the two fiscal years, down from prior expectations for a 7% to 9% rise. It also anticipates wine and spirits sales to be flat to up 3%, reflecting a lower bottom end than the prior estimate of 1% growth.

Per-share earnings are pegged to increase by mid-single-digits to low-double-digits for fiscal 2027 and by low-single-digits to mid-single-digits for the subsequent year, the company said. It previously estimated low-double-digit EPS growth in the medium term.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Appian Q3 revenue up 21%, beats expectations
Appian Q3 revenue up 21%, beats expectations
Nov 6, 2025
Overview * Appian Q3 total revenue grows 21% yr/yr, beating analyst expectations * GAAP net income for Q3 was $7.8 mln, compared to a loss last year * Non-GAAP operating income rose to $29.8 mln from $8.3 mln last year Outlook * Appian expects Q4 cloud subscriptions revenue between $115 mln and $117 mln * Company sees Q4 total revenue...
Insulet tops quarterly estimates on demand for wearable insulin pumps
Insulet tops quarterly estimates on demand for wearable insulin pumps
Nov 6, 2025
Nov 6 (Reuters) - Medical device maker Insulet ( PODD ) on Thursday posted third-quarter results that surpassed Wall Street's expectations on strong demand for its wearable insulin pumps, which eliminate the need for daily injections. Insulet's ( PODD ) sales have risen since the broader approval for its automated insulin delivery device, Omnipod, that can be attached to the...
Warner Bros Discovery misses quarterly revenue estimates
Warner Bros Discovery misses quarterly revenue estimates
Nov 6, 2025
(Reuters) -Warner Bros Discovery ( WBD ) fell short of Wall Street estimates for quarterly revenue on Thursday, squeezed by lackluster growth in its streaming unit and persistent declines in its cable TV business. The media conglomerate reported total revenue of $9.05 billion in the third quarter ended September, compared with analysts' average estimate of $9.15 billion, according to data...
Xeris Q3 product revenue slightly misses; updates 2025 revenue guidance
Xeris Q3 product revenue slightly misses; updates 2025 revenue guidance
Nov 6, 2025
Overview * Xeris Q3 product revenue grows 40% YoY to $74 mln, slightly missing estimates * Recorlev revenue grew 109% YoY to $37 mln, driven by increased patient demand * Company updates 2025 revenue guidance to $285-$290 mln, reflecting 42% growth at midpoint Outlook * Xeris Biopharma ( XERS ) updates 2025 revenue guidance to $285-$290 mln from $280-$290 mln...
Copyright 2023-2026 - www.financetom.com All Rights Reserved